Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
Diabetes/Metabolism Research and Reviews|April 25, 2025
Long-Term Effectiveness of Once-Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real-World StudyBenedetta Maria Bonora, Andrea Giaccari, Agostino Consoli, et al.
Current Obesity Reports|October 8, 2024
Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA TrialsGuglielmo Beccuti, Fabio Bioletto, Mirko Parasiliti-Caprino, et al.
Frontiers of Hormone Research|July 10, 2010
Ghrelin and anterior pituitary functionFabio Lanfranco, Giovanna Motta, Matteo Baldi, et al.
Diabetes, Obesity & Metabolism|October 21, 2016
Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programmeFabio Broglio, Edoardo Mannucci, Raffaele Napoli, et al.
Nutrients|June 28, 2023
The Effects of Omega 3 and Omega 6 Fatty Acids on Glucose Metabolism: An Updated ReviewFilippo Egalini, Ornella Guardamagna, Giulia Gaggero, et al.
European Journal of Endocrinology|March 13, 2002
Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humansMauro Maccario, Johannes D Veldhuis, Fabio Broglio, et al.
Pituitary|September 1, 2005
Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndromeRoberta Giordano, Andreea Picu, Fabio Broglio, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|December 12, 2023
Eicosapentaenoic Acid: between Cardiovascular Benefits and the Risk of Atrial FibrillationFilippo Egalini, Mattia Rossi, Mauro Massussi, et al.
The Journal of Clinical Endocrinology and Metabolism|March 13, 2002
Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumorsMarco Volante, Elena Allìa, Patrizia Gugliotta, et al.
The Lancet Regional Health. Europe|October 27, 2025
Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational studyGian Paolo Fadini, Andrea Giaccari, Fabio Broglio, et al.
Pageof 8